Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.488 SEK | -6.11% | +8.56% | +20.06% |
May. 23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
May. 21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
Sales 2024 * | - | Sales 2025 * | 578M 55.61M | Capitalization | 824M 79.39M |
---|---|---|---|---|---|
Net income 2024 * | -280M -26.96M | Net income 2025 * | -96M -9.24M | EV / Sales 2024 * | - |
Net Debt 2024 * | 56.6M 5.45M | Net Debt 2025 * | 657M 63.25M | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 * |
-2.08
x | P/E ratio 2025 * |
-2.4
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.23% |
Latest transcript on Cantargia AB
1 day | -6.11% | ||
1 week | +8.56% | ||
Current month | -6.50% | ||
1 month | +31.30% | ||
3 months | +64.64% | ||
6 months | +19.68% | ||
Current year | +20.06% |
Managers | Title | Age | Since |
---|---|---|---|
Göran Forsberg
CEO | Chief Executive Officer | 61 | 14-07-08 |
Patrik Renblad
DFI | Director of Finance/CFO | 54 | 23-06-14 |
David Liberg
CTO | Chief Tech/Sci/R&D Officer | 55 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Magnus Nilsson
BRD | Director/Board Member | 68 | 21-05-25 |
Chairman | 64 | 15-12-31 | |
Damian Marron
BRD | Director/Board Member | 62 | 21-05-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 4.488 | -6.11% | 314,927 |
24-06-04 | 4.78 | -4.40% | 586,387 |
24-06-03 | 5 | +4.17% | 1,045,917 |
24-05-31 | 4.8 | +11.84% | 1,642,315 |
24-05-30 | 4.292 | +3.82% | 308,080 |
Delayed Quote Nasdaq Stockholm, June 05, 2024 at 11:29 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.06% | 79.1M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.86% | 22.67B | |
-9.70% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- CANTA Stock